{"entity":{"id":"nct05797831","kind":"trial","name":"Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer","aka":[],"tldr":"A phase 2/3 trial of KRT-232 in endometrial cancer, run by Kartos Therapeutics, Inc., now recruiting.","summary":"Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer is a phase 2/3 interventional study registered as NCT05797831 by Kartos Therapeutics, Inc., with 268 participants planned, started 2023-07-17 and due to reach its primary completion in 2025-08. Interventions recorded: Navtemadlin, Navtemadlin Placebo. Conditions listed: Endometrial Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05797831","url":"https://clinicaltrials.gov/study/NCT05797831"}],"tags":["ctgov-ingest"],"related":[],"cancers":["endometrial"],"sections":[],"technologies":[],"targets":[],"drugs":["krt-232"],"companies":["kartos-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05797831","phase":"2/3","setting":"A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects With TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy","sponsor":"Kartos Therapeutics, Inc.","enrolled":268,"outcomes":[]},"route":"/trials/nct05797831/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"}],"drug":[{"id":"krt-232","kind":"drug","name":"KRT-232","route":"/drugs/krt-232/"}],"company":[{"id":"kartos-therapeutics","kind":"company","name":"Kartos Therapeutics","route":"/companies/kartos-therapeutics/"}]}}